Do your patients suffer from dry, itchy, red or burning eyes?
This may be caused by skin and eyelid inflammation that affects their eye condition. Lumenis invites you to think outside the eye and to offer your patients a solution to their skin related problems.
Skin and eyelid inflammation affects millions of people every year. Over 85% of patients also suffer from inflammatory ocular conditions, such as Melbomian Gland Dysfunction (MGD), blepharities, eyelid inflammation and eyelid telangiectasia.
The Lumenis M22™ combines Intense Pulsed Light (IPL) with unique Optimal Pulse Technology (OPT™).
When using IPL on your patient’s facial skin, especially in vicinity to the eyelids, efficacy and safety are essential. OPT™ is the most advance IPL technology, developed by Lumenis and is unique to the Lumenis M22™.
“Although rosacea is predominantly a skin condition, it often leads to eyelid and ocular surface inflammation, which can then trigger melbomian gland dysfunction (MGD), the major cause of dry eye disease (DED)” (Ronald N Gaster, MD)
“Many of the patients who received IPL with OPTtreatment (for rosacea) reported that symptoms such as dry/itchy eyes improved and decreased their need for artificial tears.” (Rolando Toyos, MD)
“DED (Dry Eye Disease) and aesthetics are two big opportunities for expanding an ophthalmology practice. A single technology, intense pulsed light, could offer solutions to both.” (Steven J. Dell, MD)